Biora Therapeutics, Inc. (BIORQ)

Market Cap	442.00 +10,950.0%
Revenue (ttm)	892.00K +4,855.6%
Net Income	-31.54M
EPS	-10.46
Shares Out	4.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	562
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0050
Beta	157.85
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Biora Therapeutics

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 58
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIORQ

Financial Performance

In 2023, Biora Therapeutics's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 19, 2026

Data Sources Report a data error